The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

STFX     7-[(4R)-4-amino-6- azaspiro[2.4]heptan-6...

Synonyms: Sitafloxacin, SureCN74553, CHEMBL108821, AC-1388, DU-6859a, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Sitafloxacin


High impact information on Sitafloxacin

  • DQ-113 was compared in vitro to sitafloxacin, moxifloxacin, levofloxacin, and ciprofloxacin for potential to select mutational resistance in multiresistant staphylococci, pneumococci, and enterococci [5].
  • The mean +/- standard error of the mean viable bacterial counts in murine lungs infected with PSSP and treated with DX-619, sitafloxacin, ciprofloxacin (10 mg/kg twice daily), and saline (twice daily) were 1.75 +/- 0.06, 1.92 +/- 0.23, 6.48 +/- 0.28, and 7.57 +/- 0.13 log10 CFU/ml, respectively [6].
  • In murine lung infections caused by PSSP, the 50% effective doses (ED50s) of DX-619, sitafloxacin, and ciprofloxacin were 9.15, 11.1, and 127.6 mg/kg of body weight, respectively [6].
  • Exposure to DK-507k and sitafloxacin resulted in mutations, mostly in gyrA [7].
  • These results indicated that, compared with other available quinolones, sitafloxacin maintained higher activity against recent clinical isolates with multiple mutations in gyrA and parC, which can be explained by the high inhibitory activities of sitafloxacin against both mutated enzymes [8].

Chemical compound and disease context of Sitafloxacin


Biological context of Sitafloxacin


Anatomical context of Sitafloxacin


Associations of Sitafloxacin with other chemical compounds


Gene context of Sitafloxacin


Analytical, diagnostic and therapeutic context of Sitafloxacin


  1. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone. Nakane, T., Iyobe, S., Sato, K., Mitsuhashi, S. Antimicrob. Agents Chemother. (1995) [Pubmed]
  2. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tomioka, H., Sato, K., Akaki, T., Kajitani, H., Kawahara, S., Sakatani, M. Antimicrob. Agents Chemother. (1999) [Pubmed]
  3. The new 4-quinolones DU-6859a and DV-7751a show enhanced activity against Streptococcus pneumoniae. Morrissey, I., Smith, J.T. Drugs (1995) [Pubmed]
  4. Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci. Forstall, G.J., Knapp, C.C., Washington, J.A. Antimicrob. Agents Chemother. (1994) [Pubmed]
  5. In Vitro Studies with DQ-113 and Comparison Fluoroquinolones To Determine Propensities To Select Resistance in Gram-Positive Cocci. Hong, S.G., Moland, E.S., Wickman, P.A., Black, J.A., Hossain, A., Hanson, N.D., Thomson, K.S. Antimicrob. Agents Chemother. (2007) [Pubmed]
  6. In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. Fukuda, Y., Yanagihara, K., Ohno, H., Higashiyama, Y., Miyazaki, Y., Tsukamoto, K., Hirakata, Y., Tomono, K., Mizuta, Y., Tashiro, T., Kohno, S. Antimicrob. Agents Chemother. (2006) [Pubmed]
  7. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents. Browne, F.A., Bozdogan, B., Clark, C., Kelly, L.M., Ednie, L., Kosowska, K., Dewasse, B., Jacobs, M.R., Appelbaum, P.C. Antimicrob. Agents Chemother. (2003) [Pubmed]
  8. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Akasaka, T., Tanaka, M., Yamaguchi, A., Sato, K. Antimicrob. Agents Chemother. (2001) [Pubmed]
  9. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Sato, K., Hoshino, K., Tanaka, M., Hayakawa, I., Osada, Y. Antimicrob. Agents Chemother. (1992) [Pubmed]
  10. In vitro activity of gemifloxacin (SB 265805) against anaerobes. Goldstein, E.J., Citron, D.M., Warren, Y., Tyrrell, K., Merriam, C.V. Antimicrob. Agents Chemother. (1999) [Pubmed]
  11. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Child, J., Andrews, J., Boswell, F., Brenwald, N., Wise, R. J. Antimicrob. Chemother. (1995) [Pubmed]
  12. In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin. Tanaka, M., Wada, N., Kurosaka, S.M., Chiba, M., Sato, K., Hiramatsu, K. J. Antimicrob. Chemother. (1998) [Pubmed]
  13. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Nakashima, M., Uematsu, T., Kosuge, K., Umemura, K., Hakusui, H., Tanaka, M. Antimicrob. Agents Chemother. (1995) [Pubmed]
  14. Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies. Niki, Y., Itokawa, K., Okazaki, O. Antimicrob. Agents Chemother. (1998) [Pubmed]
  15. Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis. Mikamo, H., Kawazoe, K., Sato, Y., Izumi, K., Tamaya, T. J. Antimicrob. Chemother. (1998) [Pubmed]
  16. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV. Touyama, M., Higa, F., Nakasone, C., Shinzato, T., Akamine, M., Haranaga, S., Tateyama, M., Nakasone, I., Yamane, N., Fujita, J. J. Antimicrob. Chemother. (2006) [Pubmed]
  17. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Hagiwara, T., Satoh, S., Kasai, Y., Takasuna, K. Jpn. J. Pharmacol. (2001) [Pubmed]
  18. The effect of DU-6859a, a new potent fluoroquinolone, on fecal microflora in human volunteers. Inagaki, Y., Yamamoto, N., Chida, T., Okamura, N., Tanaka, M. The Japanese journal of antibiotics. (1995) [Pubmed]
  19. Pharmacokinetics, tissue distribution, and excretion of sitafloxacin, a new fluoroquinolone antibiotic, in rats, dogs, and monkeys. Tachibana, M., Tanaka, M., Mitsugi, K., Jin, Y., Takaichi, M., Okazaki, O. Arzneimittel-Forschung. (2004) [Pubmed]
  20. Quinolone activity against anaerobes. Appelbaum, P.C. Drugs (1999) [Pubmed]
  21. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. Sánchez, J.E., Sáenz, N.G., Rincón, M.R., Martín, I.T., Sánchez, E.G., Martínez, M.J. J. Antimicrob. Chemother. (2000) [Pubmed]
  22. Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes. Tachibana, M., Tanaka, M., Masubuchi, Y., Horie, T. Drug Metab. Dispos. (2005) [Pubmed]
  23. Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. Shetty, N., Wilson, A.P. J. Antimicrob. Chemother. (2000) [Pubmed]
  24. Possible relationship between phototoxicity and photodegradation of sitafloxacin, a quinolone antibacterial agent, in the auricular skin of albino mice. Shimoda, K., Ikeda, T., Okawara, S., Kato, M. Toxicol. Sci. (2000) [Pubmed]
  25. An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia. Feldman, C., White, H., O'Grady, J., Flitcroft, A., Briggs, A., Richards, G. Int. J. Antimicrob. Agents (2001) [Pubmed]
  26. In vitro activities of 11 fluoroquinolones against 226 Campylobacter jejuni strains isolated from Finnish patients, with special reference to ciprofloxacin resistance. Lehtopolku, M., Hakanen, A.J., Siitonen, A., Huovinen, P., Kotilainen, P. J. Antimicrob. Chemother. (2005) [Pubmed]
  27. Molecular surveillance of European quinolone-resistant clinical isolates of Pseudomonas aeruginosa and Acinetobacter spp. using automated ribotyping. Brisse, S., Milatovic, D., Fluit, A.C., Kusters, K., Toelstra, A., Verhoef, J., Schmitz, F.J. J. Clin. Microbiol. (2000) [Pubmed]
  28. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci. Kaneko, A., Sasaki, J., Shimadzu, M., Kanayama, A., Saika, T., Kobayashi, I. J. Antimicrob. Chemother. (2000) [Pubmed]
  29. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates. Jones, R.N., Johnson, D.M., Biedenbach, D.J., Marshall, S.A. Diagn. Microbiol. Infect. Dis. (1995) [Pubmed]
WikiGenes - Universities